Our recent data from an NSCLC patient responding to RT and ipilimumab provide supportive evidence that RT can enhance the expression of an immunogenic mutation in the irradiated tumor and can lead to priming of neoantigen-specific CD8 T cells [25]. Here, CD8A is linked to neoplasm.